John Verniero
Vice President, Us Commercial Operations @Celltrion USA
Signup · Get unlimited contacts
WORK HISTORY
Vice President, Us Commercial Operations @Celltrion USA
Jersey City, NJ, US
Celltrion Healthcare conducts worldwide development, marketing, sales, and distribution of biological medicines through an extensive global network that spans more than 110 different countries, via subsidiaries in 32 countries and 38 global partners. Celltrion’s leadership in biosimilars is evidenced by the approval of Celltrion’s Remsima® which is the world\'s first approved biosimilar monoclonal antibody.In this role, I am part of the inaugural U.S. Commercial Team and have built from scratch and lead the US Commercial Operations group, with responsibilities including Pricing & Contracting, Trade & Distribution, GPOs, Field Reimbursement and Patient Services, Commercial Field-Based Operations, and Analytics.
EDUCATION
Duke University - The Fuqua School of Business
Master of Business Administration - MBA, Finance
Drew University
B.A., Economics, Political Science
SKILLS
ABOUT JOHN VERNIERO
I develop strategic plans which can be operationalized that unlock new products and achieve sustained growth for leading biopharmaceutical and precision medicine data and healthcare technology enterprises by driving exceptional implementation. I have been successful in both US and global roles, leading diverse functions including Finance & Accounting teams in Denmark and Japan, Sales & Marketing/Commercial Teams in Japan, Market Research and Strategy Teams in Switzerland/EU, and Biopharmaceutical and Medical Technology Sales, Marketing, Pricing, GPO, Trade, Patient Support Services, Sales Operations, Key Account Management, Finance, Data Analytics, and Software Product Management Teams in the United States. A sample of my accomplishments includes:• Set-up an entire US Commercial Operations infrastructure in six months in order to launch, on time, three biopharmaceutical products.• Increased in first nine months customer base of a healthcare technology start-up from 5 (prior to my joining) to 23.• Turned around multi-million dollar precision oncology data solutions division loss into multi-million dollar profit within first year amidst COVID-19 pandemic.• Transformed two different multi-billion dollar biotech franchises while exceeding revenue and EBITDA goals.• Introduced industry-first oncology medical benefit patient co-pay card - FIRST STEP.• Shaped global biosimilar regulatory landscape by leading initiative to develop strategies and tactics relating to anticipated first-ever market entry of biosimilar therapeutic proteins.• Led oversubscribed pre-Series A funding round in 2022.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.